Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

Analysis: China plays hardball with ex-diplomat's seizure

Dec 12, 2018

BEIJING — China is playing hardball with the detention of a former Canadian diplomat days after Canada arrested a leading Chinese executive. In many ways it looks like a classic Chinese response to perceived slights: Deny any wrongdoing, seize the moral high ground and exert maximum pressure to extract concessions. But Beijing's detention of Michael Kovrig also reflects an increasingly bold approach to international disputes under President Xi Jinping, who has overseen a vast expansion of China's diplomatic, military and economic power. China has often retaliated against foreign governments and corporations in diplomatic disputes, but rarely by holding a foreign...

China and US discuss plans for trade talks

Dec 12, 2018

BEIJING — China's economy czar and U.S. trade envoys discussed plans for talks on a tariff battle, the government said Tuesday, indicating that negotiations are going ahead despite tension over the arrest of a Chinese tech executive. Vice Premier Liu He talked by phone with Treasury Secretary Steven Mnuchin and U.S. Trade Representative Robert Lighthizer about "the promotion of the next economic and trade consultations," said a two-sentence Commerce Ministry statement. It gave no other details. Lighthizer's office confirmed the phone call with Liu but provided no additional information. The announcement indicated that talks are on track despite China's weekend...

Asian shares mixed on concerns over trade, economic outlook

Dec 12, 2018

SINGAPORE — Asian markets were mixed Tuesday in narrow trading on doubts that U.S. and China can manage to resolve their festering trade dispute. KEEPING SCORE: Japan's benchmark Nikkei 225 lost 0.4 percent to 21,127.00 and South Korea's Kospi added less than 0.1 percent to 2,055.07. Hong Kong's Hang Seng edged 0.1 percent higher to 25,768.25. The Shanghai Composite rose 0.3 percent to 2,586.47. Australia's S&P/ASX 200 added 0.2 percent to 5,562.50. Shares rose in Taiwan but fell in Singapore and Indonesia. WALL STREET: Buying of technology companies spurred gains for U.S. indexes after steep losses in early trading. China...

Gene-editing Chinese scientist kept much of his work secret

Dec 12, 2018

SHENZHEN, China — The Chinese scientist who says he helped make the world's first gene-edited babies veered off a traditional career path, keeping much of his research secret in pursuit of a larger goal — making history. He Jiankui's outsized aspirations began to take shape in 2016, the year after another team of Chinese researchers sparked global debate with the revelation that they had altered the DNA of human embryos in the lab. He soon set his mind on pushing the boundaries of medical ethics even further. The China-born, U.S.-trained scientist once confided to his former Stanford University adviser his...

World markets rise despite Trump's renewed tariff threat

Dec 12, 2018

SINGAPORE — World markets were mostly higher on Tuesday despite U.S. President Donald Trump saying it's "highly unlikely" he'll hold off on raising tariffs ahead of a closely-watched meeting with his Chinese counterpart. KEEPING SCORE: Germany's DAX index gained 0.3 percent to 11,381.78 and France's CAC 40 added 0.2 percent to 5,006.05. Britain's FTSE 100 index was flat at 7,037.15. Wall Street was set for a moderate start. Futures for the broad S&P 500 index rose 0.1 percent to 2,671.20. Dow futures also gained 0.1 percent to 24,621.00. ASIA'S DAY: Japan's benchmark Nikkei 225 added 0.6 percent to 21,952.40 and...

Sign up now!